Xerostomia Therapeutics Market Outlook:
Xerostomia Therapeutics Market size was valued at approximately USD 1.89 billion in 2025 and is projected to reach around USD 2.78 billion by the end of 2035, rising at a CAGR of approximately 3.93% during the forecast period 2026-2035. In 2026, the xerostomia therapeutics is evaluated at USD 1.97 billion.
The research and development in the market are mainly focused on regenerative solutions with advancing formulations. The advent of gene therapy, mainly AAV-mediated options for the delivery, is under clinical trials. Simultaneously, efforts are being made in cell therapy that include stromal cell infusions. Additionally, progenitor cell research and tissue engineering biobanks are enabling predictive models. In the coming years, results from the ongoing trials amalgamated with the advancements in organoid-based screening. These factors are projected to shape the modern therapeutics in xerostomia.
Additionally, the supply chain of the market plays a prominent role in revolutionizing the trajectory of growth. The supply chain for the market majorly depends on the availability of APIs such as cevimeline, along with the stem cell lines for emerging cell therapies. Hospitals and online pharmacy networks are widely spreading their reach. Also, the availability of efficient cold chain logistics is crucial to ensure the viability of the product. Market players and governments are working hand in hand to make a resilient and well-coordinated supply chain to ensure the timely availability and accessibility of next-generation regenerative therapies.
